Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY 4.0Japanese Journal of Radiology

Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study

  • Yoichi Otomi1
  • Takayoshi Shinya1
  • Hideki Otsuka1
  • Hiroto Kasai1
  • Tomoki Matsushita1
  • Yukiko Takaoka1
  • Yuka Hiroshima1
  • Tomoyasu Matsubara2
  • Koji Fujita2
  • Yukiko Tomioka3
  • Masahito Nakataki3
  • Shusuke Numata3
2 more authors
  • Yuishin Izumi2
  • Masafumi Harada1
  1. 1Department of Radiology, Tokushima University Hospital, Tokushima, Japan
  2. 2Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
  3. 3Department of Psychiatry, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
Read full textPDFDOICite

Abstract

Purpose: To evaluate changes in amyloid burden on serial amyloid PET before and after donanemab treatment in a real-world clinical cohort.

Methods: This retrospective study included 20 consecutive patients who underwent serial amyloid PET before and after donanemab treatment. Quantitative analysis was performed using Centiloid values and tracer-specific standardized uptake value ratios (SUVr). Visual assessment was also performed to determine amyloid-positive or amyloid-negative status before and after treatment.

Results: Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to − 5.6 ± 16.5 at follow-up, with a mean change of − 58.0 (p < 0.001). All patients showed a reduction in Centiloid values. In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both p < 0.001). On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment.

Conclusion: Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort. Quantitative amyloid PET, particularly using Centiloid scaling, may be a useful tool for monitoring treatment response in clinical practice.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11604-026-02054-x.

Related

  1. Spatial patterns of amyloid clearance after donanemab: A preliminary 12‐month real‐world amyloid PET study in Japanese patients with early Alzheimer's disease
    Yuki Kujuro, Marina Saito, Manami Maruko +4
    Alzheimer's & Dementia : Diagnosis, Assessment & Disease MonitoringPeer-reviewedCC BY-NC 4.0Full textPhysiologyPMC
  2. Rapid Pain Reduction and Wound Closure Following Treatment With an Amorphous Silica-Based Fiber Wound Matrix in Partial-Thickness Thermal Burns: A Case Report.
    Adam M Jorgensen, William L Hickerson
    CureusPeer-reviewedCC BYFull text1 citedEpidemiology & public healthEurope PMC
  3. ALT Reduction Following Pemafibrate Treatment in MASLD and MetALD with Dyslipidemia: Associations with the Baseline Liver Enzyme Levels
    Takako Nomura, Masafumi Ono, Kiyoyuki Kobayashi +8
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthJ-STAGE
  4. Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?
    Lieza G Exalto, Juliette L van Alphen, Frederik Barkhof +4
    Alzheimer's & dementia : the journal of the Alzheimer's AssociationPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Routine Forearm Cast Splitting in Pediatric Patients Following Closed Reduction
    Lavell Manuopangai, Jihae Abou El Ela, Viren Kasipersad
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{otomi2026serial,
  title = {{Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study}},
  author = {Yoichi Otomi and Takayoshi Shinya and Hideki Otsuka and Hiroto Kasai and Tomoki Matsushita and Yukiko Takaoka and Yuka Hiroshima and Tomoyasu Matsubara and Koji Fujita and Yukiko Tomioka and Masahito Nakataki and Shusuke Numata and Yuishin Izumi and Masafumi Harada},
  journal = {Japanese Journal of Radiology},
  year = {2026},
  month = jul,
  doi = {10.1007/s11604-026-02054-x},
  url = {https://doi.org/10.1007/s11604-026-02054-x},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study
AU  - Yoichi Otomi
AU  - Takayoshi Shinya
AU  - Hideki Otsuka
AU  - Hiroto Kasai
AU  - Tomoki Matsushita
AU  - Yukiko Takaoka
AU  - Yuka Hiroshima
AU  - Tomoyasu Matsubara
AU  - Koji Fujita
AU  - Yukiko Tomioka
AU  - Masahito Nakataki
AU  - Shusuke Numata
AU  - Yuishin Izumi
AU  - Masafumi Harada
PY  - 2026
DA  - 2026/07/27
JO  - Japanese Journal of Radiology
DO  - 10.1007/s11604-026-02054-x
UR  - https://doi.org/10.1007/s11604-026-02054-x
AB  - Purpose: To evaluate changes in amyloid burden on serial amyloid PET before and after donanemab treatment in a real-world clinical cohort.  Methods: This retrospective study included 20 consecutive patients who underwent serial amyloid PET before and after donanemab treatment. Quantitative analysis was performed using Centiloid values and tracer-specific standardized uptake value ratios (SUVr). Visual assessment was also performed to determine amyloid-positive or amyloid-negative status before and after treatment.  Results: Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to − 5.6 ± 16.5 at follow-up, with a mean change of − 58.0 (p < 0.001). All patients showed a reduction in Centiloid values. In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both p < 0.001). On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment.  Conclusion: Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort. Quantitative amyloid PET, particularly using Centiloid scaling, may be a useful tool for monitoring treatment response in clinical practice.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11604-026-02054-x.
SN  - 1867-1071
SN  - 1867-108X
ER  -